Goodenberger MKL, Thomas BC, Riegert-Johnson D, C Boland R, Plon SE, Clendenning M, Win AKo, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, Lu KH, Thibodeau S, Lindor NM.
PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016;18(1):13-9.
Göktuna SI, Canli O, Bollrath J, Fingerle AA, Horst D, Diamanti MA, Pallangyo C, Bennecke M, Nebelsiek T, Mankan AK, Lang R, Artis D, Hu Y, Patzelt T, Ruland J, Kirchner T, M Taketo M, Chariot A, Arkan MC, Greten FR.
IKKα Promotes Intestinal Tumorigenesis by Limiting Recruitment of M1-like Polarized Myeloid Cells. Cell Rep. 2022;38(9):110471.
Gogokhia L, Buhrke K, Bell R, Hoffman B, D Brown G, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF, Porter N, Martens E, O'Connell R, Jacob V, Scherl E, Crawford C, W Stephens Z, Casjens SR, Longman RS, Round JL.
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis. Cell Host Microbe. 2019;25(2):285-299.e8.
Goettel JA, Kotlarz D, Emani R, Canavan JB, Konnikova L, Illig D, Frei SM, Field M, Kowalik M, Peng K, Gringauz J, Mitsalis V, Wall SM, Tsou A, Griffith AE, Friedman JR, Towne JE, Plevy SE, Hall AO'Hara, Snapper SB.
Low-Dose Interleukin-2 Ameliorates Colitis in a Preclinical Humanized Mouse Model. Cell Mol Gastroenterol Hepatol. 2019;.
Goc J, Lv M, Bessman NJ, Flamar A-L, Sahota S, Suzuki H, Teng F, Putzel GG, Eberl G, Withers DR, Arthur JC, Shah MA, Sonnenberg GF.
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. Cell. 2021;184(19):5015-5030.e16.
Glynn S, Lipkin S, Zhang T, Sboner A, Elemento O, Van Besien K, Beltran H.
The application of precision medicine in diagnosing familial Mediterranean fever. Leuk Lymphoma. 2019;60(8):2091-2093.
Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen W-P, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LMaria, Szabo E, Rosenberg DW, Lipkin SM.
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer Prev Res (Phila). 2015;8(3):222-30.